What is the Origin of Clinical Pharmacogenetics Implementation Consortium?

The term's origin is descriptive, combining "clinical" for its direct application to patient care, "pharmacogenetics" for the study of genetic influence on drug response, and "consortium" for its collaborative, multi-institutional structure. CPIC was officially established in 2010 as a joint effort between the Pharmacogenomics Knowledgebase (PharmGKB) and the NIH-funded Pharmacogenomics Research Network (PGRN).

What is the Mechanism of Clinical Pharmacogenetics Implementation Consortium?

CPIC functions by systematically reviewing all available literature and clinical data correlating specific gene variants, often single nucleotide polymorphisms (SNPs), with drug metabolism phenotypes. They then formulate comprehensive guidelines that instruct clinicians on how to adjust drug dosing or select alternative therapies based on a patient's genotype for relevant genes, such as CYP450 enzymes. This mechanism facilitates the integration of genetic information directly into the clinical decision-making process for personalized medicine.

Clinical Pharmacogenetics Implementation Consortium

Meaning

The Clinical Pharmacogenetics Implementation Consortium, commonly abbreviated as CPIC, is an international, evidence-based group dedicated to developing and publishing peer-reviewed, freely available guidelines for using pharmacogenetic test results to optimize drug therapy. This consortium translates complex genetic data into actionable clinical recommendations for healthcare providers. Their work aims to standardize the application of pharmacogenetics, ensuring that patient care is tailored to individual genetic variations in drug metabolism and response. The ultimate goal is to enhance medication efficacy and minimize adverse drug reactions.